ArticleThe Kaohsiung journal of medical sciences2025

Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan.

Szu-Jen Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.